Nektar Reports Preclinical Data Presented at AACR, Showed Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition
April 18, 2016 at 08:35 AM EDT
Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for the company's investigational immuno-stimulatory cytokine ...